Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $3.9 billion for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 2.57% year-over-year to $3.9 billion in Q1 2026; TTM through Mar 2026 was $3.9 billion, a 2.57% increase from a year earlier, with the FY2025 full-year figure at $3.9 billion, up 8.32% from the prior year.
• Total Current Liabilities climbed to $3.9 billion in Q1 2026 per VRTX's latest filing, from $3.9 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $4.5 billion in Q3 2025 and bottomed at $2.2 billion in Q1 2022.
• The 5-year median for Total Current Liabilities is $3.6 billion (2024), against an average of $3.4 billion.
• Across the five-year window, Total Current Liabilities surged 39.19% in 2022 and fell 0.33% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $2.7 billion in 2022, then increased by 29.37% to $3.5 billion in 2023, then increased by 0.48% to $3.6 billion in 2024, then grew by 8.32% to $3.9 billion in 2025, then advanced by 0.5% to $3.9 billion in 2026.
• Per Business Quant, the three latest VRTX Total Current Liabilities figures stand at $3.9 billion (Q1 2026), $3.9 billion (Q4 2025), and $4.5 billion (Q3 2025).